摘要: Ovarian cancer is the sixth most common among women worldwide, accounting for nearly 4% of all female malignancies, and it has highest fatality-to-case ratio gynecologic cancers. Globally, an estimated 230,555 new cases were diagnosed 141,452 died ovarian in 2007.1 The disease variable incidence different geographic regions ethnic groups, with a high Northern Europe U.S., low Japan developing countries. rarely under age 30 years; increases age, reaching its peak at 60 years. majority are sporadic, only 10% affected have family history breast or cancer. Hereditary frequently related to germline mutations BRCA1 BRCA2 genes, remaining being due hereditary nonpolyposis colorectal (HNPCC) Lynch Syndrome.2 - 4
springer.com
sci-hub.st 参考文章(406)
Ben Davidson, Aasmund Berner, Claes G. Trope', Tian-Li Wang, Ie-Ming Shih, Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Human Pathology. ,vol. 38, pp. 1030- 1036 ,(2007) , 10.1016/J.HUMPATH.2006.12.009
Liliane Meunier, Marie-Line Puiffe, Cécile Le Page, Abdelali Filali-Mouhim, Mario Chevrette, Patricia N. Tonin, Diane M. Provencher, Anne-Marie Mes-Masson, Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Translational Oncology. ,vol. 3, pp. 230- 238 ,(2010) , 10.1593/TLO.10103
Hiroaki Kajiyama, Fumitaka Kikkawa, Osamu Maeda, Takahiro Suzuki, Kazuhiko Ino, Shigehiko Mizutani, Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology. ,vol. 63, pp. 158- 165 ,(2002) , 10.1159/000063801
L.T. Mantovani, S. Miotti, S. Ménard, S. Canevari, F. Raspagliesi, C. Bottini, F. Bottero, M.I. Colnaghi, Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19 European Journal of Cancer. ,vol. 30, pp. 363- 369 ,(1994) , 10.1016/0959-8049(94)90257-7
M Montenarh, A Harloziñska, J K Bar, S Kartarius, J Günther, P Sedlaczek, p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer. International Journal of Oncology. ,vol. 13, pp. 605- 615 ,(1998) , 10.3892/IJO.13.3.605
Ben Davidson, Martina Skrede, Ilvars Silins, Ie-Ming Shih, Claes G. Trope, Vivi Ann Flørenes, Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma Cancer. ,vol. 110, pp. 1264- 1271 ,(2007) , 10.1002/CNCR.22918
Deepali Sachdev, Douglas Yee, Disrupting insulin-like growth factor signaling as a potential cancer therapy Molecular Cancer Therapeutics. ,vol. 6, pp. 1- 12 ,(2007) , 10.1158/1535-7163.MCT-06-0080
M.J. Duffy, C. Duggan, The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer Clinical Biochemistry. ,vol. 37, pp. 541- 548 ,(2004) , 10.1016/J.CLINBIOCHEM.2004.05.013
Whitney A Spannuth, Anil K Sood, Robert L Coleman, Farletuzumab in epithelial ovarian carcinoma. Expert Opinion on Biological Therapy. ,vol. 10, pp. 431- 437 ,(2010) , 10.1517/14712591003592069
Ying Dong, Olivia L. Tan, Daniela Loessner, Carson Stephens, Carina Walpole, Glen M. Boyle, Peter G. Parsons, Judith A. Clements, Kallikrein-Related Peptidase 7 Promotes Multicellular Aggregation via the α5β1 Integrin Pathway and Paclitaxel Chemoresistance in Serous Epithelial Ovarian Carcinoma Cancer Research. ,vol. 70, pp. 2624- 2633 ,(2010) , 10.1158/0008-5472.CAN-09-3415